Snake Oil or Super Drug: How Have Regulators and Payers Perceived New Medicines that Target Asymptomatic Conditions?
Objectives: Assess how relevant precedent within the EMA (a key regulator) and NICE (a key HTA body) can inform how such novel medicines targeting asymptomatic conditions can be brought to market from a regulatory and payor perspective. Methods: All phase 2 or phase 3 clinical trials with "...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2023-11-01
|
| Series: | Health Technology Assessment in Action |
| Subjects: | |
| Online Access: | https://htainaction.tums.ac.ir/index.php/hta/article/view/178 |